Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures
Year: 2019
Type: article
Abstract: Organoid cultures derived from colorectal cancer (CRC) samples are increasingly used as preclinical models for studying tumor biology and the effects of targeted therapies under conditions capturing in vitro the genetic make-up of heterogeneous and even individual neoplasms. While 3D cultures are initiated from surgical specimens comprising multiple cell populations, the impact of tumor heterogeneity on drug effects in organoid cultures has not been addressed systematically. Here we have used a cohort of well-characterized CRC organoids to study the influence of tumor heterogeneity on the activity of the KRAS/MAPK-signaling pathway and the consequences of treatment by inhibitors targeting EGFR and downstream effectors. MAPK signaling, analyzed by targeted proteomics, shows unexpected heterogeneity irrespective of RAS mutations and is associated with variable responses to EGFR inhibition. In addition, we obtained evidence for intratumoral heterogeneity in drug response among parallel "sibling" 3D cultures established from a single KRAS-mutant CRC. Our results imply that separate testing of drug effects in multiple subpopulations may help to elucidate molecular correlates of tumor heterogeneity and to improve therapy response prediction in patients.
Source: PLoS Genetics
Institutions: German Cancer Research Center, Deutsches Konsortium für Translationale Krebsforschung, Charité – Universitätsmedizin Berlin, University of Freiburg, Innsbruck Medical University, Universität Innsbruck, Medical University of Graz, Otto-von-Guericke-Universität Magdeburg, Natural and Medical Sciences Institute, University of Tübingen
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,350
OpenAlex ID: W2930890990
